drugset
drugset / Trial / NCT05102552

Evaluating the Safety and Relative Bioavailability of Three SPN-817 Treatments (A, B and C) in Healthy Adult Subjects

NCT05102552 ↗

Phase 0 Completed 30 enrolled Supernus Pharmaceuticals, Inc.
RandomizedCrossoverOpen-labelOther

Summary

Randomized, Open-Label, Multiple Dose study to evaluate the relative bioavailability of Treatment A, Treatment B, and Treatment C

Timeline

Start
2021-10-19
Primary completion
2022-03-25
Completion
2022-08-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator BIS-001 Unknown — —
Comparator SPN-817 Unknown — —

Indications

No indication recorded.